News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Critical Biologics Corporation to Use Scarab Genomics' Clean Genome E. coli to Produce Recombinant Human Plasma Gelsolin


4/29/2010 11:46:39 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Critical Biologics Corporation (CBC) and Scarab Genomics announced today a strategic agreement to substantially increase the manufacturing yield of CBC’s lead therapeutic protein candidate, Solinex™, an intravenous formulation of recombinant human plasma gelsolin (rhu-pGSN). Solinex™ is in Phase 2 development to determine whether plasma gelsolin replacement therapy can prevent critically ill patients from developing many of the life-threatening complications that appear to be strongly associated with hypogelsolinemia, including acute respiratory distress syndrome (ARDS), severe sepsis syndrome, multiple organ system failure (MOSF) and death.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES